Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Stopped In a limited number of patients, no additional activity was evident for the combination vs. loncastuximab tesirine monotherapy.

Conditions

• Diffuse Large B-Cell Lymphoma
• Mantle Cell Lymphoma
• Follicular Lymphoma

Interventions

• DRUG: Loncastuximab Tesirine and Durvalumab

Sponsor

ADC Therapeutics S.A.